Status:
RECRUITING
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Metastatic Castration-resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCR...
Eligibility Criteria
Inclusion
- Willing and able to provide written informed consent;
- 18 years of age and above;
- Documented histopathology or cytopathology of PCa, adenocarcinoma;
- Confirmed as mCRPC;
- Initiated olaparib + abiraterone after site activation
Exclusion
- Patients participating in a clinical trial with an investigational prostate cancer treatment within 30 days prior to olaparib initiation
Key Trial Info
Start Date :
February 14 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06380738
Start Date
February 14 2024
End Date
January 31 2027
Last Update
December 26 2025
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aschaffenburg, Germany
2
Research Site
Augsburg, Germany
3
Research Site
Bergisch Gladbach, Germany
4
Research Site
Berlin, Germany